Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Breast Cancer (HR+/ HER2-)”

266 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 266 results

Testing effectiveness (Phase 2)Study completedNCT03659136
What this trial is testing

The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

Who this might be right for
Breast Neoplasms
Boehringer Ingelheim 103
Testing effectiveness (Phase 2)UnknownNCT06000033
What this trial is testing

Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Qilu Hospital of Shandong University 35
Not applicableWithdrawnNCT07076680
What this trial is testing

A Real-World Study in Patients With HR+/HER2- Advanced Breast Cancer

Who this might be right for
Breast Cancer MetastaticHR+/HER2- Advanced Breast Cancer
SciClone Pharmaceuticals
Testing effectiveness (Phase 2)UnknownNCT04941885
What this trial is testing

Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus Aromatase Inhibitor in Metastatic HER2+/HR+ Breast Cancer

Who this might be right for
Breast Cancer
Sun Yat-sen University 78
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07164976
What this trial is testing

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Nagoya City University 86
Testing effectiveness (Phase 2)Looking for participantsNCT05810870
What this trial is testing

PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin

Who this might be right for
Breast CancerAdvanced Breast CancerMetastatic Breast Cancer
MedSIR 14
Testing effectiveness (Phase 2)UnknownNCT03913234
What this trial is testing

Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients

Who this might be right for
HER2-positive Breast CancerPostmenopausalMetastatic Breast Cancer
Yonsei University 95
Not applicableStudy completedNCT05153135
What this trial is testing

Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 4,320
Early research (Phase 1)Looking for participantsNCT07369505
What this trial is testing

Sapu003 in Advanced mTOR-sensitive Solid Tumors

Who this might be right for
Breast Cancer MetastaticRenal Cell Carcinoma (RCC)Neuroendocrine Tumors+2 more
SAPU NANO (US) LLC 27
Testing effectiveness (Phase 2)UnknownNCT04033172
What this trial is testing

Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )

Who this might be right for
Breast CancerHER2-positive Breast Cancer
Chinese Academy of Medical Sciences 40
Large-scale testing (Phase 3)Study completedNCT03462251
What this trial is testing

Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line

Who this might be right for
Breast CancerHormone Receptor Positive TumorHER 2 Negative Breast Cancer
iOMEDICO AG 41
Testing effectiveness (Phase 2)Study completedNCT03227328
What this trial is testing

CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO

Who this might be right for
Hormone Receptor Positive Breast CancerMetastatic Breast CancerHormone Receptor Negative Breast Cancer
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 52
Not applicableStudy completedNCT07363434
What this trial is testing

A Real-world Study of Indian Patients With Advanced Breast Cancer Treated With Ribociclib

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 335
Testing effectiveness (Phase 2)Looking for participantsNCT05205200
What this trial is testing

Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02

Who this might be right for
Breast CancerMetastatic Cancer
Fudan University 338
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07336771
What this trial is testing

JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast Cancer (LABC)
Jiangsu Alphamab Biopharmaceuticals Co., Ltd 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT05625087
What this trial is testing

Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

Who this might be right for
Breast Cancer Stage IV
UNICANCER 162
Not applicableStudy completedNCT04517318
What this trial is testing

Treatment After Palbociclib-containing Regimens

Who this might be right for
Breast Cancer
Fudan University 200
Early research (Phase 1)Study completedNCT03685331
What this trial is testing

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast CancerAdvanced Breast Cancer+2 more
Abramson Cancer Center at Penn Medicine 9
Large-scale testing (Phase 3)Looking for participantsNCT06312176
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Who this might be right for
Breast Neoplasms
Merck Sharp & Dohme LLC 1,200
Early research (Phase 1)Looking for participantsNCT06678269
What this trial is testing

Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerStage IV Breast CancerBreast Cancer+5 more
Memorial Sloan Kettering Cancer Center 28
Load More Results